Linda Sasset
Senior Scientist RenBio
Linda has extensive experience in studying molecular and cellular processes, particularly in the context of cardiovascular diseases and diabetes. Her postdoctoral fellowship at Weill Cornell Medical College focused on the regulation and role of sphingolipids in health and disease. Dr. Sasset’s research has led to the discovery of Nogo-A as a negative regulator of SPT activity, which helps preserve beneficial autophagy and metabolic gene expression. Her work has been instrumental in understanding the role of sphingolipids in cardiovascular diseases and diabetes, contributing to the development of novel therapeutic strategies.
Seminars
Thursday 16th July 2026
DNA-Encoded Metabolic Transformation by Leveraging In Vivo Protein Production to Redefine Durability & Dosing Paradigms Beyond Incretin Agonism
8:30 am
- Harnessing the “Bio-Blueprint” via MYO Technology™ by utilizing proprietary DNAencoded plasmid delivery to transform skeletal muscle or subcutaneous adipocytes into a sustainable bio-factory, enabling the continuous, endogenous production of therapeutic proteins that bypass the pharmacokinetic “spikes” and “troughs” of traditional biologics
- Engineering long-acting metabolic resilience by deploying the LNP-based Prometheus system to deliver genetic instructions for multi-pathway modulators (such as EX4 or modified GLP-1/GIP) that remain localized and active for over six months, providing a “one-and-done” metabolic reset that significantly improves liver and pancreatic function without systemic toxicity
- Pioneering a “Zero-Adherence” Treatment Framework by eliminating the psychological and physical hurdles of “jab fatigue” by replacing weekly or daily injections with ultra-long-acting DNA therapeutics, ensuring real-world efficacy that matches clinical trial performance by removing patient adherence from the therapeutic equation
